Download PDF
J Neurol Surg B Skull Base 2022; 83(S 02): e580-e590
DOI: 10.1055/s-0041-1735874
Original Article

Ki-67/MIB-1 and Recurrence in Pituitary Adenoma

Kent Tadokoro 
1   Department of Otolaryngology—Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois, United States
,
Colten Wolf
1   Department of Otolaryngology—Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois, United States
,
Joseph Toth
2   State University of New York Upstate Medical University, Syracuse, New York, United States
,
Cara Joyce
3   Department of Biostatistics, Loyola University Stritch School of Medicine, Maywood, Illinois, United States
,
Meharvan Singh
4   Department of Cell and Molecular Physiology, Loyola University Chicago, Chicago, Illinois United States
,
Anand Germanwala
5   Department of Neurosurgery, Loyola University Medical Center, Maywood, Illinois, United States
,
Chirag Patel 
1   Department of Otolaryngology—Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois, United States
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Objectives Ki-67/MIB-1 is a marker of cellular proliferation used as a pathological parameter in the clinical assessment of pituitary adenomas, where its expression has shown utility in predicting the invasiveness of these tumors. However, studies have shown variable results when using Ki-67/MIB-1 association with recurrence. The purpose of this study is to determine if a high Ki-67/MIB-1 labeling index (LI) is predictive of recurrence in pituitary adenomas.

Methods A retrospective chart review was performed for patients undergoing pituitary adenoma resection with at least 1 year of follow-up. Additionally, systematic data searches were performed and included studies that correlated recurrence rate to Ki-67/MIB-1 LI. Our institutional data were included in a synthesis with previously published data.

Results Our institutional review included 79 patients with a recurrence rate of 26.6%. We found that 8.8% of our patients had a high Ki-67/MIB-1 LI (>3%); however, high Ki-67/MIB-1 was not associated with recurrence. The systematic review identified 244 articles and 49 full-text articles that were assessed for eligibility. Quantitative analysis was performed on 30 articles including our institutional data and 18 studies reported recurrence by level of Ki-67/MIB-1 LI. Among studies that compared Ki-67/MIB-1 ≥3 vs. <3%, 10 studies reported odds ratios (OR) greater than 1 of which 6 were statistically significant. A high Ki-67/MIB-1 had higher odds of recurrence via the pooled odds ratio (OR = 4.15, 95% confidence interval [CI]: 2.31–7.42).

Conclusion This systematic review suggests that a high Ki-67/MIB-1 should prompt an increased duration of follow-up due to the higher odds of recurrence of pituitary adenoma.

Keywords

pituitary adenoma - Ki-67 - MIB-1 - recurrence


Publication History

Received: 05 April 2021

Accepted: 11 August 2021

Article published online:
21 September 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182 (03) 311-322
    CrossrefPubMedGoogle Scholar
  • 2 Karamitopoulou E, Perentes E, Tolnay M, Probst A. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 1998; 29 (02) 140-145
    CrossrefPubMedGoogle Scholar
  • 3 Hu H-Y, Liu H, Zhang J-W, Hu K, Lin Y. Clinical significance of Smac and Ki-67 expression in pancreatic cancer. Hepatogastroenterology 2012; 59 (120) 2640-2643
    PubMedGoogle Scholar
  • 4 Nabi U, Nagi AH, Sami W. Ki-67 proliferating index and histological grade, type and stage of colorectal carcinoma. J Ayub Med Coll Abbottabad 2008; 20 (04) 44-48
    PubMedGoogle Scholar
  • 5 Morimoto R, Satoh F, Murakami O. et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 2008; 55 (01) 49-55
    CrossrefPubMedGoogle Scholar
  • 6 Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H. Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 1984; 2 (04) 365-371
    CrossrefPubMedGoogle Scholar
  • 7 Thapar K, Kovacs K, Scheithauer BW. et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996; 38 (01) 99-106 , discussion 106–107
    CrossrefPubMedGoogle Scholar
  • 8 Raverot G, Vasiljevic A, Jouanneau E. Prognostic factors of regrowth in nonfunctioning pituitary tumors. Pituitary 2018; 21 (02) 176-182
    CrossrefPubMedGoogle Scholar
  • 9 Roelfsema F, Biermasz NR, Pereira AM. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 2012; 15 (01) 71-83
    CrossrefPubMedGoogle Scholar
  • 10 Al-Shraim M, Asa SL. The 2004 World Health Organization classification of pituitary tumors: what is new?. Acta Neuropathol 2006; 111 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 11 Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 2003; 73 (09) 712-716
    CrossrefPubMedGoogle Scholar
  • 12 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 (02) 377-381
    CrossrefPubMedGoogle Scholar
  • 13 Mizoue T, Kawamoto H, Arita K, Kurisu K, Tominaga A, Uozumi T. MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Acta Neurochir (Wien) 1997; 139 (05) 426-431 , discussion 431–432
    CrossrefPubMedGoogle Scholar
  • 14 Nakabayashi H, Sunada I, Hara M. Immunohistochemical analyses of cell cycle-related proteins, apoptosis, and proliferation in pituitary adenomas. J Histochem Cytochem 2001; 49 (09) 1193-1194
    CrossrefPubMedGoogle Scholar
  • 15 Espay AJ, Azzarelli B, Williams LS, Bodensteiner JB. Recurrence in pituitary adenomas in childhood and adolescence. J Child Neurol 2001; 16 (05) 364-367
    CrossrefPubMedGoogle Scholar
  • 16 Hentschel SJ, McCutcheon E, Moore W, Durity FA. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci 2003; 30 (03) 215-219
    CrossrefPubMedGoogle Scholar
  • 17 Filippella M, Galland F, Kujas M. et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 2006; 65 (04) 536-543
    CrossrefPubMedGoogle Scholar
  • 18 Dubois S, Guyétant S, Menei P. et al. Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 2007; 157 (02) 141-147
    CrossrefPubMedGoogle Scholar
  • 19 Mahta A, Haghpanah V, Lashkari A, Heshmat R, Larijani B, Tavangar SM. Non-functioning pituitary adenoma: immunohistochemical analysis of 85 cases. Folia Neuropathol 2007; 45 (02) 72-77
    PubMedGoogle Scholar
  • 20 Gejman R, Swearingen B, Hedley-Whyte ET. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 2008; 39 (05) 758-766
    CrossrefPubMedGoogle Scholar
  • 21 Noh T-W, Jeong HJ, Lee M-K, Kim TS, Kim SH, Lee EJ. Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2009; 94 (11) 4406-4413
    CrossrefPubMedGoogle Scholar
  • 22 Widhalm G, Wolfsberger S, Preusser M. et al. Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg 2009; 111 (03) 563-571
    CrossrefPubMedGoogle Scholar
  • 23 Matsuyama J. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Neurol Med Chir (Tokyo) 2012; 52 (08) 563-569
    CrossrefPubMedGoogle Scholar
  • 24 Righi A, Agati P, Sisto A. et al. A classification tree approach for pituitary adenomas. Hum Pathol 2012; 43 (10) 1627-1637
    CrossrefPubMedGoogle Scholar
  • 25 Magagna-Poveda A, Leske H, Schmid C, Bernays R, Rushing EJ. Expression of somatostatin receptors, angiogenesis and proliferation markers in pituitary adenomas: an immunohistochemical study with diagnostic and therapeutic implications. Swiss Med Wkly 2013; 143: w13895
    PubMedGoogle Scholar
  • 26 Righi A, Morandi L, Leonardi E. et al. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Hum Pathol 2013; 44 (11) 2400-2409
    CrossrefPubMedGoogle Scholar
  • 27 Sánchez-Tejada L, Sánchez-Ortiga R, Moreno-Pérez O. et al. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness. Endocrinol Nutr 2013; 60 (07) 358-367
    CrossrefPubMedGoogle Scholar
  • 28 Trouillas J, Roy P, Sturm N. et al; members of HYPOPRONOS. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 2013; 126 (01) 123-135
    CrossrefPubMedGoogle Scholar
  • 29 Chiloiro S, Bianchi A, Doglietto F. et al. Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary 2014; 17 (03) 267-276
    PubMedGoogle Scholar
  • 30 Šteňo A, Bocko J, Rychlý B. et al. Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth. Acta Neurochir (Wien) 2014; 156 (03) 451-461 , discussion 461
    CrossrefPubMedGoogle Scholar
  • 31 Landeiro JA, Fonseca EO, Monnerat ALC, Taboada GF, Cabral GAPS, Antunes F. Nonfunctioning giant pituitary adenomas: invasiveness and recurrence. Surg Neurol Int 2015; 6: 179
    CrossrefPubMedGoogle Scholar
  • 32 Kim JS, Lee YS, Jung MJ, Hong YK. The predictive value of pathologic features in pituitary adenoma and correlation with pituitary adenoma recurrence. J Pathol Transl Med 2016; 50 (06) 419-425
    CrossrefPubMedGoogle Scholar
  • 33 Song Y-J, Chen M-T, Lian W. et al. Surgical treatment for male prolactinoma: a retrospective study of 184 cases. Medicine (Baltimore) 2017; 96 (02) e5833
    CrossrefPubMedGoogle Scholar
  • 34 Sadeghipour A, Mahouzi L, Salem MM. et al. Ki67 labeling correlated with invasion but not with recurrence. Appl Immunohistochem Mol Morphol 2017; 25 (05) 341-345
    CrossrefPubMedGoogle Scholar
  • 35 Matoušek P, Buzrla P, Reguli Š, Krajča J, Dvořáčková J, Lipina R. Factors that predict the growth of residual nonfunctional pituitary adenomas: correlations between relapse and cell cycle markers. BioMed Res Int 2018; 2018: 1876290
    CrossrefPubMedGoogle Scholar
  • 36 Antunes X, Ventura N, Camilo GB. et al. Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine 2018; 60 (03) 415-422
    CrossrefPubMedGoogle Scholar
  • 37 Lv L, Hu Y, Yin S. et al. Clinically aggressive phenotype: A clinicopathological case series of atypical pituitary adenomas. Clin Neurol Neurosurg 2018; 167: 93-98
    CrossrefPubMedGoogle Scholar
  • 38 Liu X, Feng M, Zhang Y. et al. Expression of matrix metalloproteinase-9, pituitary tumor transforming gene, high mobility group A 2, and Ki-67 in adrenocorticotropic hormone-secreting pituitary tumors and their association with tumor recurrence. World Neurosurg 2018; 113: e213-e221
    CrossrefPubMedGoogle Scholar
  • 39 Hasanov R, Aydoğan Bİ, Kiremitçi S, Erden E, Güllü S. The prognostic roles of the Ki-67 proliferation index, P53 expression, mitotic index, and radiological tumor invasion in pituitary adenomas. Endocr Pathol 2019; 30 (01) 49-55
    CrossrefPubMedGoogle Scholar
  • 40 Asioli S, Righi A, Iommi M. et al. Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. Eur J Endocrinol 2019; 180 (02) 127-134
    CrossrefPubMedGoogle Scholar
  • 41 Nikitin PV, Ryzhova MV, Shishkina LV, Shugay SV, Zubova IV. Study of simple immunohistochemical cytocolorimetric assay application for more accurate assessment of prognosis in patients with pituitary adenomas. World Neurosurg 2019; 122: e1047-e1051
    CrossrefPubMedGoogle Scholar
  • 42 Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 2008; 37 (01) 151-171 , xi
    CrossrefPubMedGoogle Scholar
  • 43 Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27 (05) 485-534
    CrossrefPubMedGoogle Scholar
  • 44 McCoul ED, Bedrosian JC, Akselrod O, Anand VK, Schwartz TH. Preservation of multidimensional quality of life after endoscopic pituitary adenoma resection. J Neurosurg 2015; 123 (03) 813-820
    CrossrefPubMedGoogle Scholar
  • 45 Bhenswala PN, Schlosser RJ, Nguyen SA, Munawar S, Rowan NR. Sinonasal quality-of-life outcomes after endoscopic endonasal skull base surgery. Int Forum Allergy Rhinol 2019; 9 (10) 1105-1118
    CrossrefPubMedGoogle Scholar
  • 46 Aaltomaa S, Lipponen P, Vesalainen S, Ala-Opas M, Eskelinen M, Syrjänen K. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 1997; 32 (04) 410-415
    CrossrefPubMedGoogle Scholar
  • 47 Bettencourt M-C, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156 (03) 1064-1068
    CrossrefPubMedGoogle Scholar
  • 48 Weikel W, Brumm C, Wilkens C, Beck T, Knapstein PG. Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detect Prev 1995; 19 (05) 446-450
    PubMedGoogle Scholar
  • 49 Micko ASG, Wöhrer A, Wolfsberger S, Knosp E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 2015; 122 (04) 803-811
    CrossrefPubMedGoogle Scholar
  • 50 Gerges MM, Rumalla K, Godil SS. et al. Long-term outcomes after endoscopic endonasal surgery for nonfunctioning pituitary macroadenomas. J Neurosurg 2020; x: 1-12
    PubMedGoogle Scholar
  • 51 Dallapiazza RF, Grober Y, Starke RM, Laws Jr. ER, Jane Jr JA. Long-term results of endonasal endoscopic transsphenoidal resection of nonfunctioning pituitary macroadenomas. Neurosurgery 2015; 76 (01) 42-52 , discussion 52–53
    CrossrefPubMedGoogle Scholar
  • 52 Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin Endocrinol (Oxf) 2003; 58 (06) 763-769
    CrossrefPubMedGoogle Scholar
  • 53 Lv L, Yin S, Zhou P. et al. Clinical and pathologic characteristics predicted the postoperative recurrence and progression of pituitary adenoma: a retrospective study with 10 years follow-up. World Neurosurg 2018; 118: e428-e435
    CrossrefPubMedGoogle Scholar
  • 54 Soto-Ares G, Cortet-Rudelli C, Assaker R. et al. MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas. Eur J Endocrinol 2002; 146 (02) 179-186
    CrossrefPubMedGoogle Scholar
  • 55 Park P, Chandler WF, Barkan AL. et al. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 2004; 55 (01) 100-106 , discussion 106–107
    CrossrefPubMedGoogle Scholar
  • 56 Chang EF, Zada G, Kim S. et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 2008; 108 (04) 736-745
    CrossrefPubMedGoogle Scholar
  • 57 Chen Y, Wang CD, Su ZP. et al. Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 2012; 96 (04) 333-342
    CrossrefPubMedGoogle Scholar
  • 58 Brochier S, Galland F, Kujas M. et al. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 2010; 163 (02) 193-200
    CrossrefPubMedGoogle Scholar
  • 59 Ziu M, Dunn IF, Hess C. et al. Congress of neurological surgeons systematic review and evidence-based guideline on posttreatment follow-up evaluation of patients with nonfunctioning pituitary adenomas. Neurosurgery 2016; 79 (04) E541-E543
    CrossrefPubMedGoogle Scholar